Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 02 Oct, 14:16 UTC

In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.

fintechscience

Sources

• T2Novartis wagers almost $8B on a Chinese biotech’s RNA drugsBioPharma Dive / Healthcare Dive / MedTech Dive02 Oct, 14:16